TRASTUREL 150MG ING

About

Trastuzumab, known as Trasturel, is a targeted biological therapy, a humanized monoclonal antibody designed to specifically bind to the human epidermal growth factor receptor 2 (HER2) protein. HER2 is a receptor tyrosine kinase that, when overexpressed on the surface of cancer cells, drives aggressive tumor growth and proliferation in certain types of breast and gastric cancers. By attaching to HER2, trastuzumab blocks its signaling pathways, inhibits cell growth, and can trigger the immune system to destroy HER2-positive cancer cells through antibody-dependent cell-mediated cytotoxicity.

This precise mechanism of action makes Trasturel a cornerstone treatment for HER2-positive malignancies, significantly improving prognosis and extending survival when used alone or in combination with chemotherapy. It is administered intravenously, offering a tailored approach for patients whose tumors overexpress HER2, thereby providing a more effective and less toxic treatment option compared to conventional chemotherapy alone by directly targeting the cancer-driving protein.

Uses

• HER2-positive Early Breast Cancer
• HER2-positive Metastatic Breast Cancer
• HER2-positive Metastatic Gastric Adenocarcinoma
• HER2-positive Gastroesophageal Junction Cancer

Directions For Use

Administer intravenously as an infusion under strict medical supervision. Dosage and frequency are determined by body weight and treatment regimen.

Benefits

• Specifically targets HER2-overexpressing cancer cells
• Inhibits cancer cell proliferation
• Enhances immune response against tumors
• Improves disease-free and overall survival
• Reduces the risk of cancer recurrence
• Offers a tailored approach for HER2-positive patients

Side Effects

• Fever and chills (infusion reactions)
• Nausea and vomiting
• Diarrhea
• Headache
• Fatigue
• Cardiomyopathy (heart muscle weakness)
• Anemia
• Neutropenia
• Rash
• Cough
• Dyspnea
• Peripheral edema

Safety Measures

• Alcohol - No direct interaction, but patients should consult their doctor regarding alcohol use during cancer treatment due to potential systemic effects.
• Pregnancy - Contraindicated due to significant risks of fetal harm, including severe oligohydramnios and pulmonary hypoplasia. Use effective contraception.
• Breastfeeding - Not recommended; discontinue breastfeeding during treatment and for at least 7 months after the last dose due to potential harm to the infant.
• Liver - Use with caution in patients with severe hepatic impairment; monitor liver function tests regularly.
• Kidney - No specific dose adjustment required for renal impairment; monitor renal function, especially if co-administered with nephrotoxic drugs.
• Lung - Monitor for pulmonary toxicity, including interstitial pneumonitis; use with caution in patients with pre-existing lung disease.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.